Arvinas at the Piper Sandler Healthcare Conference
Arvinas, Inc. (NASDAQ: ARVN), a pioneering clinical-stage biotechnology company, is set to take part in the esteemed Piper Sandler 37th Annual Healthcare Conference. On Thursday, December 4, the company's Chief Medical Officer Noah Berkowitz, M.D., Ph.D., and Chief Financial Officer Andrew Saik will engage in a captivating fireside chat that promises to highlight the company's groundbreaking innovations in targeted protein degradation.
Live Presentation and Webcast
For those interested in the intricate details of Arvinas' presentation, a live audio webcast of this discussion will be available online. Attendees will find the webcast accessible through the Events and Presentations section on the company's official website, ensuring that anyone can catch the insights shared during this highly anticipated event.
About Arvinas
Arvinas, recognized for its forward-thinking approach, is committed to transforming the treatment landscape for patients battling severe and life-altering diseases. The company's innovative protein degrader platform, known as PROTAC (PROteolysis TArgeting Chimera), leverages the body's own protein disposal mechanisms to selectively target and eliminate proteins that contribute to disease, thereby presenting an exciting new frontier in drug development.
Current Research Endeavors
Currently, Arvinas is making significant strides in multiple investigational drugs. Notable among these are ARV-102, which addresses LRRK2 for neurodegenerative disorders, ARV-393, aimed at tackling BCL6 in relapsed/refractory non-Hodgkin Lymphoma, and ARV-806, which focuses on KRAS G12D for various mutated cancers, including pancreatic and colorectal types. Another noteworthy candidate is vepdegestrant, developed to target the estrogen receptor in patients with advanced ER+/HER2- breast cancer.
Company Location and Contact Information
Arvinas proudly operates from New Haven, Connecticut, where its team is dedicated to revolutionizing how medicine approaches disease management. For additional information regarding Arvinas, prospective collaborators and investors can visit www.arvinas.com.
Contact Details:
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
Frequently Asked Questions
What is the purpose of Arvinas' presentation at the conference?
Arvinas aims to showcase its advancements in targeted protein degradation and discuss its innovative drug development pipeline.
Who are the key speakers at the event?
Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, and Andrew Saik, Chief Financial Officer, will represent Arvinas during the discussion.
How can one access the presentation?
The presentation will be available via a live audio webcast, details of which will be posted on the company's website under the Events and Presentations section.
What is PROTAC technology?
PROTAC stands for PROteolysis TArgeting Chimera, a groundbreaking approach that utilizes the body's natural processes to selectively degrade disease-causing proteins.
Where is Arvinas located?
Arvinas is based in New Haven, Connecticut, focusing on developing therapies for serious diseases.